Skip to main content
. Author manuscript; available in PMC: 2018 Feb 6.
Published in final edited form as: Mol Carcinog. 2016 May 25;56(2):402–411. doi: 10.1002/mc.22503

Fig. 3. Characterization of Gem Resistant cells.

Fig. 3

GEM resistant BxPC-3 (A) and Capan-2 (B) cells were treated with indicated doses of gemcitabine (GEM) for 24h and proliferation was measured as described in methods. (C) Whole cell lysates prepared from Capan-2 WT and GEM resistant GRC cells were assessed for alterations in STAT3, pSTAT3, pp65, pIκBα and β–actin using Western blot analysis. (D & E) GEM resistant BxPC-3 and Capan-2 cells were treated with indicated doses of Nexrutine (Nx) for 24h and proliferation was measured as described in methods. Data is presented as average±SD from three independent experiments conducted in triplicate. P values: * <0.05; ** <0.001; *** <0.0005.